WuXi Of China Sale To Charles River Of U.S. Hit By Advisor Opposition
This article was originally published in PharmAsia News
Executive Summary
A proposal to buy China's WuXi Pharma Tech faced another obstacle when U.S.-based Charles River shareholders were advised by a corporate risk-management firm to reject it